| Autor: |
Maria Caterina Schipani, Flaminia Tomassetti, Isabella Polidori, Paola Ricci, Maria Loredana Frassanito, Silva Seraceni, Maria Morello, Eleonora Nicolai, Stefano Aquaro, Sergio Bernardini, Massimo Pieri, Graziella Calugi |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Diseases, Vol 10, Iss 2, p 25 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2079-9721 |
| DOI: |
10.3390/diseases10020025 |
| Popis: |
(1) Background: The production of anti-SARS-CoV-2 antibodies should help minimize the severity of COVID-19 disease. Our focus was to investigate and compare different vaccination schedules, monitoring circulating S-RBD Ab (antibodies anti—Spike protein—Receptor Binding Domain) levels after administering two doses in naïve patients. Likewise, vaccine-stimulated immunity in naïve and previously infected patients was compared. (2) Methods: We included 392 patients. Sera were evaluated by Elecsys anti-SARS-CoV-2 S. Statistical analyses were conducted by MedCalc and JASP. (3) Results: In COVID-19 patients, the median value of Ab levels was 154 BAU/mL, stable up to 9 months after the infection. From the data observed in vaccinated patients, higher median values were recorded in COVID-19/Pfizer BioNTech (18913 BAU/mL) than in other groups (Pfizer BioNTech: 1841; ChadOx1 961; heterologous vaccination: 2687) BAU/mL. (4) Conclusions: In conclusion, a single booster dose given to previously infected patients raised an antibody response much higher than two doses given to naïve individuals and heterologous vaccination generated a robust persistent antibody response at high levels, steady up to three months after administration. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
